Form 4: ESSA Pharma CEO Disposes Shares in Acquisition

ESSA Pharma's President and CEO, David Parkinson, reported the disposal of all his common shares as part of the company's acquisition by Xeno Acquisition Corp.

Summary

• David Parkinson, President and CEO, and a Director of ESSA Pharma Inc., reported a change in beneficial ownership.
• On October 9, 2025, Parkinson disposed of 65,675 common shares of ESSA Pharma Inc.
• This transaction resulted in Parkinson holding 0 common shares following the reported transaction.
• The disposal was pursuant to a Business Combination Agreement dated July 13, 2025, amended September 23, 2025.
• Under the agreement, Xeno Acquisition Corp. acquired all outstanding common shares of ESSA Pharma Inc.
• Shareholders received approximately US$0.12 in cash per share and one Contingent Value Right (CVR) per share, potentially worth up to US$0.14 per CVR.

Sentiment

Score: 7

Explanation: The report details the completion of an acquisition, providing liquidity to shareholders through cash and potential future value via CVRs. While the CVR introduces some contingency, the overall event represents a definitive strategic outcome for the company and its shareholders.

Positives

• The acquisition provides a clear exit strategy and liquidity for ESSA Pharma shareholders.
• Shareholders receive a combination of immediate cash and potential future value through CVRs.

Negatives

• ESSA Pharma Inc. common shares will no longer be publicly traded following the acquisition.
• The CVRs introduce uncertainty regarding the final per-share value, as their payout is contingent.

Risks

• The value of the Contingent Value Rights (CVRs) is not guaranteed and depends on future events or milestones.
• Shareholders will no longer participate in the future growth or potential upside of ESSA Pharma Inc. as an independent entity.

Future Outlook

The completion of a business combination where ESSA Pharma Inc. was acquired suggests its future as an independent public entity has concluded. The future value for former shareholders is tied to the performance and payout of the Contingent Value Rights.

Management Comments

• This report is a factual record of a transaction and does not contain direct quotes or paraphrased statements from management beyond the transaction details.

Industry Context

This acquisition reflects ongoing consolidation within the biotechnology or pharmaceutical sector, where smaller companies are often acquired by larger entities for their assets, pipeline, or strategic fit. The use of CVRs is a common mechanism in biotech M&A to bridge valuation gaps and share future risks/rewards.

Comparison to Industry Standards

• The use of Contingent Value Rights (CVRs) in biotech acquisitions is a standard practice, often seen in deals where the acquired company has pipeline assets with uncertain future milestones, similar to transactions involving companies like Acceleron Pharma (acquired by Merck) or MyoKardia (acquired by Bristol Myers Squibb), where CVRs were used to provide additional consideration tied to clinical or regulatory achievements.
• The per-share cash consideration of US$0.12, combined with a potential US$0.14 CVR, suggests a total potential value of US$0.26 per share. This valuation would need to be compared to ESSA Pharma's historical trading prices and analyst targets prior to the acquisition announcement to assess its fairness relative to industry benchmarks for similar-stage biotech companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, losing direct ownership in ESSA Pharma Inc.
• Employees: Likely subject to integration into Xeno Acquisition Corp. or XenoTherapeutics, Inc., with potential changes in roles or employment status.
• Management: David Parkinson, as President and CEO, has disposed of his shares, indicating the end of his direct equity stake in the acquired entity.

Next Steps

• Payouts for Contingent Value Rights (CVRs) will occur within specified periods following the close of the transactions, contingent on certain events.

Key Dates

Recommendation

The company has been acquired, and its common shares are no longer publicly traded. Shareholders would have tendered their shares for the cash and CVR consideration. Therefore, there is no longer an opportunity to 'buy' or 'hold' the stock in its previous form. The recommendation reflects the completed transaction.

Keywords

ESSA Pharma, EPIX, Xeno Acquisition Corp, XenoTherapeutics, XOMA Royalty Corporation, Business Combination Agreement, Acquisition, Merger, Contingent Value Right, CVR, Insider Transaction, Form 4, David Parkinson